{"id":1017625,"date":"2026-11-05T11:00:59","date_gmt":"2026-11-05T16:00:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/"},"modified":"2026-11-05T11:00:59","modified_gmt":"2026-11-05T16:00:59","slug":"organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/","title":{"rendered":"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl1 { padding-left: 5px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth50 { width: 50% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Organon to Present New Analysis on VTAMA<sup>\u00ae<\/sup> (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting<\/b><\/p>\n<p class=\"bwalignc\"><i>New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroups<\/i><\/p>\n<p>JERSEY CITY, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nOrganon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in patients with moderate to severe atopic dermatitis (AD) will be presented at the 2026 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting, taking place in Phoenix, Arizona.<\/p>\n<p>\nThe analysis evaluates the efficacy of VTAMA cream across diverse patient subgroups based on baseline percent body surface area (BSA) affected and other baseline characteristics.<\/p>\n<p><span class=\"bwuline\">Details for the presentation are as follows<\/span>:<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwwidth50 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Abstract Title<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwwidth50 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Session\/Presentation Details:<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwwidth50 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTapinarof Cream 1% in Atopic Dermatitis: Consistent Efficacy Over Time Across %BSA and Other Subgroups<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwwidth50 bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSaturday, November 14, 4:30 &#8211; 6:00 pm (MT); VTAMA to be presented 5:13 pm-5:23 pm (MT)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nVTAMA cream is the only aryl hydrocarbon receptor (AhR) agonist indicated for the treatment of both plaque psoriasis in adults and AD in adults and pediatric patients ages 2 years and older.<\/p>\n<p><b>About the Phase 3 Program for VTAMA cream in Atopic Dermatitis<\/b><\/p>\n<p>\nADORING was the Phase 3 AD clinical development program for VTAMA cream, consisting of two 8-week pivotal trials, ADORING 1 (NCT05014568) and ADORING 2 (NCT05032859), as well as ADORING 3 (NCT05142774), a 48-week, open-label, long-term extension trial.<\/p>\n<p><b><span class=\"bwuline\">About VTAMA<\/span><\/b><\/p>\n<p><b>INDICATIONS:<\/b> VTAMA<sup>\u00ae<\/sup> (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nthe topical treatment of plaque psoriasis in adults<\/p>\n<\/li>\n<li>\nthe topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older<\/p>\n<\/li>\n<\/ul>\n<p><b>SELECTED SAFETY INFORMATION<\/b><\/p>\n<p><b>Adverse Events:<\/b> In plaque psoriasis, the most common adverse reactions (incidence \u22651%) were: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.<\/p>\n<p><b>Adverse Events:<\/b> In atopic dermatitis, the most common adverse reactions (incidence \u22651%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.<\/p>\n<p><b>Before prescribing VTAMA cream, please read the <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.organon.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2FVTAMA%2Fvtama_pi_ppi_combo.pdf&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=1&amp;md5=e69731e55e41d4fea0db92bad1ee79db\"><b>Prescribing Information<\/b><\/a><b>.<\/b><\/p>\n<p><b><span class=\"bwuline\">About Organon<\/span><\/b><\/p>\n<p>\nOrganon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women\u2019s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately, or differently affect women, while expanding access to essential treatments in over 140 markets.<\/p>\n<p>\nHeadquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.organon.com%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911899344%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DtKCOYU9vOLmDCTcWEb78bIZkuNDXd%252FDCaFpmAXlvpmA%253D%26reserved%3D0&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=www.organon.com&amp;index=2&amp;md5=eef0633cdd249ee94317e8c848884439\">www.organon.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Forganon%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911924697%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DXpwhK7dRFG4u0%252BtB6G3zuil0nV8BmZEg5PesVDdjQRg%253D%26reserved%3D0&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=0ceb11d31b05aa43987546f6a32754d6\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.instagram.com%252Forganonllc%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911936373%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DqSg1VM84RxtKG6QfoItRTlHJRW5y41wCaOhpLSJxtPc%253D%26reserved%3D0&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=b05fc7bd96555cafd638a9c3474bcfe9\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fx.com%252FOrganonLLC%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911949591%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DeNbT%252B%252Bj03w5tIXxRnwJEaolZePGmNi70pPL3bdaBqB8%253D%26reserved%3D0&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=X&amp;index=5&amp;md5=711a7f77bd75fe0290c06275bdf44c39\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.youtube.com%252Fchannel%252FUCFXZcWljXuEhDkMCmZZ4Yzw%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911965966%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DOg8MAaURoWgydvBUAsbzysy2m1CB8MPigwCnj6ExGoQ%253D%26reserved%3D0&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=b183b26729a3e9c40838ca21fa81d558\">YouTube<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.tiktok.com%252F%2540organon_llc%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911978302%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DuJyzKNE%252BI7PIJqk1ALN3CSuX%252BnT1HlV%252Ba2Y4sdtQ22Q%253D%26reserved%3D0&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=TikTok&amp;index=7&amp;md5=bc6cb8e72645accaf56fc550df3c3834\">TikTok<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.facebook.com%252FOrganonLLC%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911991988%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DL32i3wTDxRkuvRdV%252BvbEx4BxQwEzlcgX%252FMghX5QCxLs%253D%26reserved%3D0&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=723daca789d87b37118c8365947bbdde\">Facebook<\/a>.<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including statements regarding the planned presentation of data at the ACAAI Annual Scientific Meeting. Forward-looking statements may be identified by words such as \u201cwill\u201d or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon\u2019s filings with the SEC, including Organon\u2019s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54633732&amp;newsitemid=20261105927902&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=a71a0c64dbc06673efa0cae2123cf68e\">www.sec.gov<\/a>). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\n\u00a9 2026 Organon group of companies. All rights reserved. US-VTA-113528 10\/26<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261105927902\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261105927902\/en\/<\/a><\/span><\/p>\n<p>\nMedia Contact:<br \/>\n<br \/>Felicia Bisaro<br \/>\n<br \/>(646) 703-1807<\/p>\n<p>Investor Contact:<br \/>\n<br \/>Jennifer Halchak<br \/>\n<br \/>(201) 275-2711<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Arizona New Jersey<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261105927902\/en\/1899942\/3\/Organon_Logo_No_tagline.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroups JERSEY CITY, N.J.&#8211;(BUSINESS WIRE)&#8211; Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in patients with moderate to severe atopic dermatitis (AD) will be presented at the 2026 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting, taking place in Phoenix, Arizona. The analysis evaluates the efficacy of VTAMA cream &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroups JERSEY CITY, N.J.&#8211;(BUSINESS WIRE)&#8211; Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in patients with moderate to severe atopic dermatitis (AD) will be presented at the 2026 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting, taking place in Phoenix, Arizona. The analysis evaluates the efficacy of VTAMA cream &hellip; Continue reading &quot;Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T16:00:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting\",\"datePublished\":\"2026-11-05T16:00:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/\"},\"wordCount\":693,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/\",\"name\":\"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-05T16:00:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting - Market Newsdesk","og_description":"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroups JERSEY CITY, N.J.&#8211;(BUSINESS WIRE)&#8211; Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in patients with moderate to severe atopic dermatitis (AD) will be presented at the 2026 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting, taking place in Phoenix, Arizona. The analysis evaluates the efficacy of VTAMA cream &hellip; Continue reading \"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T16:00:59+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting","datePublished":"2026-11-05T16:00:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/"},"wordCount":693,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/","name":"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-05T16:00:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105927902r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Organon to Present New Analysis on VTAMA\u00ae (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma &amp; Immunology Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}